Brief: Xvivo Perfusion Q4 Reported EBITDA Falls To SEK 8.5 Million
Jan 30 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* A HISTORIC YEAR ENDED WITH A QUARTER OF SALES RECORDS
* Q4 NET SALES OF NON-DURABLE GOODS IN QUARTER AMOUNTED TO
SEK
59.4 (52.3) MILLION
* Q4 REPORTED EBITDA AMOUNTED TO SEK 8.5 (10.5) MILLION,
CORRESPONDING TO AN EBITDA MARGIN OF 14 PERCENT (18)
Source text for Eikon: ID:nWkrbwjC83
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength